Response of striosomal opioid signaling to dopamine depletion in 6-hydroxydopamine-lesioned rat model of Parkinson's disease: A potential compensatory role

Frontiers in Cellular Neuroscience

Volumn , Issue MAY, 2013, Pages

  Koizumi, Hidetaka ^a,b   Morigaki, Ryoma ^a   Okita, Shinya ^a   Nagahiro, Shinji ^a   Kaji, Ryuji ^a   Nakagawa, Masanori ^c   Goto, Satoshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Dopamine; Opioid receptors; Parkinson's disease; Striatum; Striosomes

Indexed keywords

DELTA OPIATE RECEPTOR; DOPAMINE; ISOPROPAMIDE IODIDE; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; OPIATE RECEPTOR; OXIDOPAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DEGLYCOSYLATION; DORSAL STRIATUM; GENE AMPLIFICATION; IMMUNOHISTOCHEMISTRY; MALE; MICROSCOPY; MOLECULAR WEIGHT; MOSAICISM; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PROTEIN DEPLETION; PROTEIN LOCALIZATION; PUTAMEN; RAT; SIGNAL TRANSDUCTION; STRIOSOME; SUBCALLOSAL STREAK;

EID: 84877285159     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2013.00074     Document Type: Article

References (71)

1. Alexander, G.E., and Crutcher, M.D. (1990). Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13, 266-271.
2. Aosaki, T., and Kawaguchi, Y. (1996). Actions of substance P on rat neostriatal neurons in vitro. J. Neurosci. 16, 5141-5153.
3. Aosaki, T., Miura, M., Suzuki, T., Nishimura, K., and Masuda, M. (2010). Acetylcholine-dopamine balance hypothesis in the striatum: an update. Geriatr. Gerontol. Int. 10 (Suppl 1), S148-S157.
4. Bezard, E., Gross, C.E., and Brotchie, J.M. (2003). Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci. 26, 215-221.
5. Blomeley, C.P., and Bracci, E. (2011). Opioidergic interactions between striatal projection neurons. J. Neurosci. 31, 13346-13356.
6. Bowen, W.D., Pert, C.B., and Pert, A. (1982). Nigral 6-hydroxydopamine lesions equally decrease μ and δ opiate binding to striatal patches: further evidence for a conformationally malleable type 1 opiate receptor. Life Sci. 31, 1679-1682.
7. Bromberg-Martin, E.S., Matsumoto, M., Nakahara, H., and Hikosaka, O. (2010). Multiple timescales of memory in lateral habenula and dopamine neurons. Neuron 67, 499-510.
8. Cahill, C.M., McClellan, K.A., Morinville, A., Hoffert, C., Hubatsch, D., O'Donnell, D., and Beaudet, A. (2001). Immunohistochemical distribution of delta opioid receptors in the rat central nervous system: evidence for somatodendritic labeling and antigen-specific cellular compartmentalization. J. Comp. Neurol. 440, 65-84.
9. Cenci, M.A., Lee, C.S., and Björklund, A. (1998). L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10, 2694-2706.
10. Chen, C., Li, J-G., Chen, Y., Huang, P., Wang, Y., and Liu-Chen, L-Y. (2006). GEC1 interacts with the κ opioid receptor and enhances expression of the receptor. J. Biol. Chem. 281, 7983-7993.
11. Christoph, G.R., Leonzio, R.J., and Wilcox, K.S. (1986). Stimulation of the lateral habenula inhibits dopamine-containing neurons in the substantia nigra and ventral tegmental area of the rat. J. Neurosci. 6, 613-619.
12. Crittenden, J.R., Cantuti-Castelvetri, I., Saka, E., Keller-McGandy, C.E., Hernandez, L.F., Kett, L.R., Young, A.B., Standaert, D.G., and Graybiel, A.M. (2009). Dysregulation of CalDAG-GEFI and CalDAG-GEFII predicts the severity of motor side effects induced by anti-parkinsonian therapy. Proc. Natl. Acad. Sci. U.S.A. 106, 2892-2896.
13. Crittenden, J.R., and Graybiel, A.M. (2011). Basal ganglia disorders associated with imbalances in the striosome and matrix compartments. Front. Neuroanat. 5, 59.
14. Dacko, S., and Schneider, J.S. (1991). Met-enkephalin immunoreactivity in the basal ganglia in symptomatic and asymptomatic MPTP-exposed monkeys: correlation with degree of parkinsonian symptoms. Neurosci. Lett. 127, 49-52.
15. Delfs, J.M., Kong, H., Mestek, A., Chen, Y., Yu, L., Reisine, T., and Chesselet, M.F. (1994). Expression of mu opioid receptor mRNA in rat brain: an in situ hybridization study at the single cell level. J. Comp. Neurol. 345, 46-68.
16. Fujiyama, F., Sohn, J., Nakano, T., Furuta, T., Nakamura, K.C., Matsuda, W., and Kaneko, T. (2011). Exclusive and common targets of neostriatofugal projections of rat striosome neurons: a single neuron-tracing study using a viral vector. Eur. J. Neurosci. 33, 668-677.
17. Garzon, J., Juarros, J.L., Castro, M.A., and Sanchez-Blazquez, P. (1995). Antibodies to the cloned μ-opioid receptor detect various molecular weight forms in areas of mouse brain. Mol. Pharmacol. 47, 738-744.
18. Georges, F., Stinus, L., Bloch, B., and Le Moine, C. (1999). Chronic morphine exposure and spontaneous withdrawal are associated with modifications of dopamine receptor and neuropeptide gene expression in the rat striatum. Eur. J. Neurosci. 11, 481-490.
19. Gerfen, C.R. (1984). The neostriatal mosaic: compartmentalization of corticostriatal input and striatonigral output systems. Nature 311, 461-464.
20. Gerfen, C.R. (1992). The neostriatal mosaic: multiple levels of compartmental organization. Annu. Rev. Neurosci. 15, 285-320.
21. Goto, S., Nagahiro, S., and Kaji, R. (2010). Striosome-matrix pathology of dystonias: a new hypothesis for dystonia genesis. In: Dystonia: causes, symptoms and treatment, (Kurstot J, Forsstrom M, eds), pp 1-22. New York, NY: Nova Science Publishers.
22. Graybiel, A.M. (1990). Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13, 244-254.
23. Graybiel, A.M. (2008). Habits, rituals, and the evaluative brain. Annu. Rev. Neurosci. 31, 359-387.
24. Guttenberg, N.D., Klop, H., Minami, M., Satoh, M., and Voorn, P. (1996). Co-localization of mu opioid receptor is greater with dynorphin than enkephalin in rat striatum. Neuroreport 7, 2119-2124.
25. Henry, A.G., White, I.J., Marsh, M., von Zastrow, M., and Hislop, J.N. (2011). The role of ubiquitination in lysosomal trafficking of δ-opioid receptors. Traffic 12, 170-184.
26. Herkenham, M., and Nauta, W.J. (1979). Efferent connections of the habenular nuclei in the rat. J. Comp. Neurol. 187, 19-47.
27. Herkenham, M., and Pert, C.B. (1981). Mosaic distribution of opiate receptors, parafascicular projections and acetylcholinesterase in rat striatum. Nature 291, 415-418.
28. Hislop, J.N., Henry, A.G., and von Zastrow, M. (2011). Ubiquitination in the first cytoplasmic loop of μ-opioid receptors reveals a hierarchial mechanism of lysosomal down-regulation. J. Biol. Chem. 286, 40193-40204.
29. Henry, A.G., White, I.J., Marsh, M., von Zastrow, M., and Hislop, J.N. (2011). The role of ubiquitination in lysosomal trafficking of δ-opioid receptors. Traffic 12, 170-184.
30. Herkenham, M., and Nauta, W.J. (1979). Efferent connections of the habenular nuclei in the rat. J. Comp. Neurol. 187, 19-47.
31. Herkenham, M., and Pert, C.B. (1981). Mosaic distribution of opiate receptors, parafascicular projections and acetylcholinesterase in rat striatum. Nature 291, 415-418.
32. Hislop, J.N., Henry, A.G., and von Zastrow, M. (2011). Ubiquitination in the first cytoplasmic loop of μ-opioid receptors reveals a hierarchial mechanism of lysosomal down-regulation. J. Biol. Chem. 286, 40193-40204.
33. Hollt, V. (1986). Opioid peptide processing and receptor selectivity. Annu. Rev. Pharmacol. Toxicol. 26, 59-77.
34. Jabourian, M., Perez, S., Ezan, P., Glowinski, J., Deniau, J.M., and Kemel, M.L. (2007) Impact of 6-hydroxydopamine lesions and cocaine exposure on μ-opioid receptor expression and regulation of cholinergic transmission in the limbic-prefrontal territory of the rat dorsal striatum. Eur. J. Neurosci. 25, 1546-1556.
35. Ji, H., and Shepard, P.D. (2007). Lateral habenula stimulation inhibits rat midbrain dopamine neurons through a GABA(A) receptor-mediated mechanism. J. Neurosci. 27, 6923-6930.
36. Jiang, Z.G., and North, R.A. (1992). Pre- and postsynaptic inhibition by opioids in rat striatum. J. Neurosci. 12, 356-361.
37. Jimenez-Castellanos, J., and Graybiel, A.M. (1989). Compartmental origins of striatal efferent projections in the cat. Neuroscience 32, 297-321.
38. Johansson, P.A., Andersson, M., Andersson, K.E., and Cenci, M.A. (2001). Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of L-DOPA-induced dyskinesia. Neurobiol. Dis. 8, 220-239.
39. Le Moine, C., Kieffer, B., Gaveriaux-Ruff, C., Befort, K., and Bloch, B. (1994). Delta-opioid receptor gene expression in the mouse forebrain: localization in cholinergic neurons of the striatum. Neuroscience 62, 635-640.
40. Leskelä, T.T., Markkanen, M.H., Pietilä, M., Tuusa, J.T., and Petaja-Repo, U.E. (2007). Opioid receptor pharmacological chaperones act by binding and stabilizing newly synthesized receptors in the endoplasmic reticulum. J. Biol. Chem. 282, 23171-23183.
41. Mansour, A., Khachaturian, H., Lewis, M.E., Akil, H., and Watson S.J. (1987). Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J. Neurosci. 7, 2445-2464.
42. Mansour, A., Thompson, R.C., Akil, H., and Watson, S.J. (1993). Delta opioid receptor mRNA distribution in the brain: comparison to delta receptor binding and proenkephalin mRNA. J. Chem. Neuroanat. 6, 351-362.
43. Mansour, A., Fox, C.A., Thompson, R.C., Akil, H., and Watson, S.J. (1994). mu-Opioid receptor mRNA expression in the rat CNS: Comparison to mu-receptor binding. Brain. Res. 643, 245-265.
44. Le Moine, C., Kieffer, B., Gaveriaux-Ruff, C., Befort, K., and Bloch, B. (1994). Delta-opioid receptor gene expression in the mouse forebrain: localization in cholinergic neurons of the striatum. Neuroscience 62, 635-640.
45. Leskelä, T.T., Markkanen, M.H., Pietilä, M., Tuusa, J.T., and Petaja-Repo, U.E. (2007). Opioid receptor pharmacological chaperones act by binding and stabilizing newly synthesized receptors in the endoplasmic reticulum. J. Biol. Chem. 282, 23171-23183.
46. Mansour, A., Khachaturian, H., Lewis, M.E., Akil, H., and Watson S.J. (1987). Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J. Neurosci. 7, 2445-2464.
47. Mansour, A., Thompson, R.C., Akil, H., and Watson, S.J. (1993). Delta opioid receptor mRNA distribution in the brain: comparison to delta receptor binding and proenkephalin mRNA. J. Chem. Neuroanat. 6, 351-362.
48. Mansour, A., Fox, C.A., Thompson, R.C., Akil, H., and Watson, S.J. (1994) mu-Opioid receptor mRNA expression in the rat CNS: Comparison to mu-receptor binding. Brain Res. 643, 245-265.
49. Mansour, A., Fox, C.A., Akil, H., and Watson, S.J. (1995). Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 18, 22-29.
50. Mansour, A., Burke, S., Pavlic, R.J., Akil, H., and Watson, S.J. (1996). Immunohistochemical localization of the cloned κ1 receptor in the rat CNS and pituitary. Neuroscience 71, 671-690.
51. Matsumoto, M., and Hikosaka, O. (2007). Lateral habenula as a source of negative reward signals in dopamine neurons. Nature 447, 1111-1115.
52. McLean, S., Rothman, R.B., and Herkenham, M. (1986). Autoradiographic localization of mu- and delta-opiate receptors in the forebrain of the rat. Brain Res. 378, 49-60.
53. Meissner, W., Dovero, S., Bioulac, B., Gross, C.E., and Bezard, E. (2003). Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei. Neurobiol. Dis. 13, 46-54.
54. Miura, M., Saino-Saito, S., Masuda, M., Kobayashi, K., and Aosaki, T. (2007). Compartment-specific modulation of GABAergic synaptic transmission by μ-opioid receptors in the mouse striatum with green fluorescent protein-expressing dopamine islands. J. Neurosci. 27, 9721-9728.
55. Miura, M., Masuda, M., and Aosaki, T. (2008). Roles of μ-opioid receptors in GABAergic synaptic transmission in the striosome and matrix compartments of the striatum. Mol. Neurobiol. 37, 104-115.
56. Morissette, M., Grondin, R., Goulet, M., Bédard, P.J., and Di Paolo, T. (1999). Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. J.Neurochem.72, 682-692.
57. Okita, S. Morigaki, R., Koizumi, H., Kaji, R., Nagahiro, S., and Goto, S. (2012). Cell type-specific localization of optineurin in the striatal neurons of mice: implications for neuronal vulnerability in Huntington's disease. Neuroscience 202, 363-370.
58. Paxinos, G., and Watson, C. (1997). The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA.
59. Pert, C.B., Kuhar, M.J., and Snyder, S.H. (1976). Opiate receptor: autoradiographic localization in rat brain. Proc. Natl. Acad. Sci. U.S.A. 73, 3729-3733.
60. Pisani, A., Bernardi, G., Ding, J., and Surmeier, J. (2007). Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci. 30, 545-553.
61. Quik, M., Police, S., Langston, J.W., and Di Monte, D.A. (2002). Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey. Neuroscience 113, 213-220.
62. Samadi, P., Bedard, P.J., and Rouillard, C. (2006). Opioids and motor complications in Parkinson's disease. Trends Pharmacol. Sci. 27, 512-517.
63. Sato, K., Sumi-Ichinose, C., Kaji, R., Ikemoto, K., Nomura, T., Nagatsu, I., Ichinose, H., Ito, M., Sako, W., Nagahiro, S., Graybiel, A.M., and Goto, S. (2008). Differential involvement of striosome and matrix dopamine systems in a transgenic model of dopa-responsive dystonia. Proc. Natl. Acad. Sci. U.S.A. 105, 12551-12556.
64. Schulz, S., Schreff, M., Koch, T., Zimprich, A., Gramsch, C., Elde, R., and Höllt, V. (1998). Immunolocalization of two mu-opioid receptor isoforms (MOR1 and MOR1B) in the rat central nervous system. Neuroscience 82, 613-622.
65. Smith, J.A., Leslie, F.M., Broide, R.S., and Loughlin, S.E. (1993). Long-term changes in striatal opioid systems after 6-hydroxydopamine lesion of rat substantia nigra. Neuroscience 55, 935-951.
66. Tokuno, H., Chiken, S., Kametani, K., and Moriizumi, T. (2002). Efferent projections from the striatal patch compartment: anterograde degeneration after selective ablation of neurons expressing mu-opioid receptor in rat. Neurosci. Lett. 332, 5-8.
67. Trovero, F., Herve, D., Desban, M., Glowinski, J., and von Zastrow, M. (1990). Striatal opiate mu-receptors are not located on dopamine nerve endings in the rat. Neuroscience 39, 313-321.
68. Waldhoer, M., Bartlett, S.E., and Whistler, J.L. (2004). Opioid receptors. Annu. Rev. Biochem. 73, 953-990.
69. Wang, H., Gracy, K.N., and Pickel, V.M. (1999). Mu-opioid and NMDA-type glutamate receptors are often colocalized in spiny neurons within patches of the caudate-putamen nucleus. J. Comp. Neurol. 412, 132-146.
70. Wang, H., and Pickel, V.M. (2001). Preferential cytoplasmic localization of δ-opioid receptors in rat striatal patches: comparison with plasmalemmal μ-opioid receptors. J. Neurosci. 21, 3242-3250.
71. Yamamura, Y., Morigaki, R., Kasahara, J., Yokoyama, H., Tanabe, A., Okita, S., Koizumi, H., Nagahiro, S., Kaji, R., and Goto, S. (2013), Dopamine signaling negatively regulates striatal phosphorylation of Cdk5 at tyrosine 15 in mice. Front. Cell. Neurosci. 7, 12.